[1] Dempsey, N, Sandoval, A, Mahtani, R. Metastatic HER2-Positive Breast Cancer: Is There an Optimal Sequence of Therapy?. Curr. Treat. Options in Oncol. 24, 1120–1137 (2023).
[2] Slamon DJ,Leyland-Jones B,Shak S,et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344:783–92.
[3] Swain S,Miles D,Kim S-B,et al. Pertuzumab,trastuzumab,and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a doubleblind,randomised,placebo-controlled,phase 3 study. Lancet Oncol 2020:21(4):519-530.
[4] Miles D,Ciruelos E,Schneeweiss,et al. Final results from the PERUSE study of first-line pertuzumab plus trastuzumab plus a taxane for HER2-positive locally recurrent or metastatic breast cancer,with a multivariable approach to guide prognostication. Ann Oncol 2021:32(10):1245-1255.
[5] Rimawi M,Ferraro J-M,De La Haba-Rodriguez J,et al. First-line trastuzumab plus an aromatase inhibitor,with or without pertuzumab,in human epidermal growth factor receptor 2-positive and hormone receptorpositive metastatic or locally advanced breast cancer (PERTAIN): a randomised,open-label phase II trial. J Clin Oncol. 2018;36(28):2826–35.
[6] Prior L,Lim M,Ward C,et al. Metastatic HER2+ breast cancer: a potentially curable disease? Cureus 2017:9(9)e1654.
[7] Haji F,Hurvitz SA. Can women with HER2-positive metastatic breast cancer be cured? Clin Breast Cancer. 2021;21(6):526–31.
[8] Verma S,Miles D,Gianni L,et al. Trastuzumab emtansine for HER2-positive advanced breast cancer (EMILIA). N Engl J Med. 2012;367:1783–91.
[9] Hurvitz S,Hegg R,Chung W-P,et al. Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03,a randomized,open-label,phase 3 trial. Lancet. 2023;401(10371):105–17.
[10] Curigliano G,Mueller V,Borges V,et al. Tucatinib versus placebo added to trastuzumab and capecitabine for patients with pretreated HER2+ metastatic breast cancer with and without brain metastases (HER2CLIMB): final overall survival analysis. Ann Oncol. 2022;33(3):321–9.
[11] Geyer C,Forster J,Lindquist D,et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer (EGF100151). N Engl J Med. 2006;355:2733–43.
[12] Blackwell K,Burstein H,Storniolo A,et al. Overall survival beneft with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF104900 study. J Clin Oncol. 2012;30(21):2585–92.
[13] Saura C,Oliveira M,Feng Y-H,et al. Neratinib plus capecitabine versus lapatinib plus capecitabine in HER2-positive metastatic breast cancer previously treated with ≥2 HER2-directed regimens: phase III NALA trial. J Clin Oncol. 2020;38:3138–49.
[14] Krop I,Kim S-B,Gonzalez Martin A,et al. Trastuzumab emtansine versus treatment of physician’s choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): final overall survival results from a randomised open-label phase 3 trial. Lancet. 2017;18(6):743–54.
[15] Rugo H,Im S-A,Cardoso F,et al. Margetuximab versus trastuzumab in patients with previously treated HER2-positive advanced breast cancer (SOPHIA): final overall survival results from a randomized phase 3 trial. JCO. 2023;41(2):198–205.
[16] Konecny G,Pauletti G,Pegram M,et al. Quantitative association between HER-2/neu and steroid hormone receptors in hormone receptor-positive primary breast cancer. J Natl Cancer Inst. 2003;95:142–53.
[17] Dowsett M,Allred C,Knox J,et al. Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER2) status with recurrence in the arimidex,tamoxifen,alone or in combination trial. J Clin Oncol. 2008;26:1059–65.
[18] Osborne CK,Schiff R. Mechanisms of endocrine resistance in breast cancer. Annu Rev Med. 2011;62:233–47.
[19] Untch M,Gelber RD,Jacksich C,et al. Estimating the magnitude of trastuzumab effects within patient subgroups in the HERA trial. Ann Oncol. 2008;19:1090–6.
[20] Brufsky A,Lembersky B,Schiffman K,et al. Hormone receptor status does not affect the clinical beneft of trastuzumab therapy for patients with metastatic breast cancer. Clin Breast Cancer. 2005;6:247–52.
[21] Tolaney S,Wardley AM,Zambelli S,,et al. Abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in women with hormone receptor-positive,HER2-positive advanced breast cancer (monarcHER): a randomised,open-label,phase 2 trial. Lancet Oncol. 2020;21(6):763–75.
[22] Andre F,Nadal JC,Denys H,et al. Final overall survival (OS) for abemaciclib plus trastuzumab +/- fulvestrant versus trastuzumab plus chemotherapy in patients with HR+ HER2+ advanced breast cancer (monarcHER): a randomized,open-label,phase 2 trial. ESMO Congress 2022,Abstract 2806 LBA 2806.
[23] Goel S,Pernas S,Tan-Wasielewski Z,et al. Ribociclib plus trastuzumab in advanced HER2-positive breast cancer: results of a phase 1b/2 trial. Clin Breast Cancer. 2019;19(6):399–404.
[24] Loibl S,Metzger O,Mandrekar SJ,et al. PATINA: a randomized,open label,phase III trial to evaluate the effcacy and safety of palbociclib + anti-HER2 therapy + endocrine therapy (ET) vs. anti-HER2 therapy + ET after induction treatment for hormone receptor positive (HR+)/HER2-positive metastatic breast cancer (MBC). Ann Oncol 2018:29(8).
[25] Perez-Fidalgo JA,Criscitiello C,Carrasco E,et al. A phase III trial of alpelisib + trastuzumab + fulvestrant versus trastuzumab + chemotherapy in HER2+ PIK3CAmutated breast cancer (ALPHABET). Future Oncol. 2022;18(19):2339–49.
[26] Keummel S,Harper-Wynne C,Park Y,et al. HeredERA breast cancer: phase III study of frst-line,fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection ± giredestrant (GDC-9545) for estrogen receptor+,HER2+ advanced breast cancer. SABCS 2022 Abstract OT2-03-01.